Palvella Therapeutics (PVLA) Gains from Investment Securities (2016 - 2024)
Historic Gains from Investment Securities for Palvella Therapeutics (PVLA) over the last 11 years, with Q3 2024 value amounting to -$843000.0.
- Palvella Therapeutics' Gains from Investment Securities fell 453684.21% to -$843000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was -$869000.0, marking a year-over-year decrease of 52184.47%. This contributed to the annual value of $489283.0 for FY2023, which is 8408.98% down from last year.
- According to the latest figures from Q3 2024, Palvella Therapeutics' Gains from Investment Securities is -$843000.0, which was down 453684.21% from -$26000.0 recorded in Q2 2024.
- In the past 5 years, Palvella Therapeutics' Gains from Investment Securities registered a high of $636000.0 during Q3 2020, and its lowest value of -$843000.0 during Q3 2024.
- For the 5-year period, Palvella Therapeutics' Gains from Investment Securities averaged around -$42368.4, with its median value being -$26000.0 (2024).
- Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 138250.0% in 2022, then tumbled by 453684.21% in 2024.
- Quarter analysis of 5 years shows Palvella Therapeutics' Gains from Investment Securities stood at -$764000.0 in 2020, then soared by 107.33% to $56000.0 in 2021, then surged by 37.5% to $77000.0 in 2022, then plummeted by 106.49% to -$5000.0 in 2023, then tumbled by 16760.0% to -$843000.0 in 2024.
- Its Gains from Investment Securities was -$843000.0 in Q3 2024, compared to -$26000.0 in Q2 2024 and $5000.0 in Q1 2024.